HC Wainwright Reduces Earnings Estimates for Vor Biopharma

Vor Biopharma Inc. (NYSE:VOR - Free Report) - Equities research analysts at HC Wainwright lowered their Q2 2025 earnings per share (EPS) estimates for Vor Biopharma in a research note issued to investors on Monday, June 30th. HC Wainwright analyst S. Ramakanth now expects that the company will post earnings of ($1.25) per share for the quarter, down from their previous forecast of ($0.18). HC Wainwright currently has a "Buy" rating and a $3.00 price target on the stock. The consensus estimate for Vor Biopharma's current full-year earnings is ($1.42) per share. HC Wainwright also issued estimates for Vor Biopharma's Q3 2025 earnings at ($0.18) EPS, Q4 2025 earnings at ($0.18) EPS, FY2025 earnings at ($0.88) EPS, Q1 2026 earnings at ($0.18) EPS, Q2 2026 earnings at ($0.18) EPS, Q3 2026 earnings at ($0.18) EPS, Q4 2026 earnings at ($0.16) EPS, FY2026 earnings at ($0.69) EPS, FY2027 earnings at ($0.65) EPS, FY2028 earnings at $0.05 EPS and FY2029 earnings at $0.24 EPS.

Other research analysts also recently issued research reports about the company. JMP Securities restated a "market perform" rating and issued a $6.00 price objective on shares of Vor Biopharma in a research note on Friday, May 9th. Baird R W downgraded shares of Vor Biopharma from a "strong-buy" rating to a "hold" rating in a report on Thursday, May 8th. Oppenheimer restated an "outperform" rating and set a $8.00 price objective on shares of Vor Biopharma in a report on Friday, March 21st. Stifel Nicolaus lowered their price objective on shares of Vor Biopharma from $12.00 to $5.00 and set a "buy" rating on the stock in a research report on Friday, March 21st. Finally, Jones Trading downgraded shares of Vor Biopharma from a "strong-buy" rating to a "hold" rating in a research report on Thursday, May 8th. Four research analysts have rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to data from MarketBeat.com, Vor Biopharma presently has an average rating of "Moderate Buy" and an average price target of $5.63.

Vor Biopharma Trading Up 1.4%

Shares of VOR traded up $0.02 on Wednesday, reaching $1.45. 25,211,367 shares of the company's stock traded hands, compared to its average volume of 4,120,309. The stock's 50 day simple moving average is $0.39 and its two-hundred day simple moving average is $0.83. The stock has a market cap of $181.19 million, a PE ratio of -0.88 and a beta of -0.51. Vor Biopharma has a 52-week low of $0.13 and a 52-week high of $2.04.

Institutional Investors Weigh In On Vor Biopharma

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the company. Two Sigma Investments LP lifted its stake in shares of Vor Biopharma by 18.9% during the 4th quarter. Two Sigma Investments LP now owns 163,064 shares of the company's stock valued at $181,000 after buying an additional 25,930 shares in the last quarter. Money Concepts Capital Corp grew its stake in Vor Biopharma by 106.1% in the 1st quarter. Money Concepts Capital Corp now owns 51,535 shares of the company's stock valued at $37,000 after buying an additional 26,535 shares in the last quarter. GABELLI & Co INVESTMENT ADVISERS INC. bought a new stake in Vor Biopharma during the 4th quarter valued at $33,000. Northern Trust Corp lifted its position in shares of Vor Biopharma by 39.0% during the fourth quarter. Northern Trust Corp now owns 157,617 shares of the company's stock worth $175,000 after acquiring an additional 44,252 shares in the last quarter. Finally, Virtu Financial LLC bought a new position in shares of Vor Biopharma in the fourth quarter worth $60,000. 97.29% of the stock is currently owned by institutional investors.

About Vor Biopharma

Vor Biopharma Inc operates as a clinical-stage cell and genome engineering company. Its lead product is tremtelectogene empogeditemcel (trem-cel), an engineered hematopoietic stem cell (eHSC) product candidate that is in phase 1/2 trial to treat acute myeloid leukemia (AML) and other hematological malignancies.